Should You Buy Amdocs Ltd (DOX) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
81.840
1 Day change
0.95%
52 Week Range
95.410
Analysis Updated At
2026/01/28
DOX is not a good buy right now for a beginner long-term investor who wants to act immediately. The stock is in a weakening technical setup (bearish momentum and sitting on/just below support), hedge funds have been aggressively selling, and recent guidance/analyst changes point to limited near-term catalysts. If you already own it, holding into the next earnings could be reasonable; if you don’t own it, I would not initiate a new position today.
Technical Analysis
Trend/momentum is currently bearish-to-weak. MACD histogram is negative (-0.256) and expanding downward, which typically signals deteriorating momentum. RSI(6) at 37.85 is weak (not deeply oversold), suggesting sellers still have control without a clear reversal signal. Moving averages are converging, consistent with a transition phase but not yet a confirmed uptrend. Key levels: Pivot 83.023; Support S1 81.828 and S2 81.089; Resistance R1 84.219 and R2 84.958. With price around ~81.7–81.8, DOX is testing support; a clean break below ~81.1 increases downside risk. Pattern-based projection also leans slightly negative over the next week/month (-1.09% / -0.78%).
**Intellectia Proprietary Trading Signals**
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Open-interest put/call at 0.25 is positioning-skew bullish (more call OI than put OI), but today’s trading flow is bearish: put/call volume is high at 3.92 (puts dominating volume). Implied volatility is elevated (IV percentile ~76.8), meaning options are priced for larger moves than usual. Net takeaway: near-term sentiment from trading flow looks cautious/bearish despite longer-positioning skew to calls, consistent with uncertainty into the next catalyst window.
Technical Summary
Sell
7
Buy
6
Positive Catalysts
on 2026-02-03 after hours could reset expectations if results/guidance surprise positively. Profitability trends are improving: latest reported quarter showed higher net income (+11.5% YoY), EPS (+15.79% YoY), and gross margin (36.17%, +7.65% YoY), which can support valuation if revenue stabilizes.
Neutral/Negative Catalysts
Technical momentum is weakening (negative and expanding MACD) while price sits on key support (~81.8), raising the risk of a breakdown. Hedge funds are selling aggressively (selling amount up 1713.29% last quarter), which is a notable sentiment headwind. Recent FY26 outlook commentary (per analyst notes) implies growth constraints and fewer near-term catalysts. Options flow is put-heavy today (bearish short-term sentiment).
Financial Performance
Latest quarter: 2025/Q4. Revenue fell to 1.150B (-8.99% YoY), showing top-line contraction. Despite that, profitability improved: net income 94.5M (+11.50% YoY), EPS 0.88 (+15.79% YoY), and gross margin 36.17% (+7.65% YoY). The key issue is that earnings growth is being driven more by margin/efficiency than revenue expansion; for long-term confidence, investors generally want to see revenue re-accelerate or clear drivers for sustainable growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent Street trend is mixed to slightly negative: price targets were trimmed (BofA to $97 from $100; Stifel to $97 from $100) while both maintained Buy ratings, indicating they still like the name but expect slower/less certain upside near-term. Wolfe Research downgraded to Peer Perform from Outperform (no price target), citing waning enthusiasm, embedded expectations in FY26 guidance, T-Mobile-related concerns, and a lack of catalysts.
Wall Street pros: improving margins/earnings power and continued Buy ratings at some firms.
Wall Street cons: constrained growth, lower-than-expected FY26 outlook versus Street expectations, and fewer clear catalysts driving multiple expansion in the near term.
Politicians/influential figures: No recent congress trading data available; insider activity is described as neutral with no significant recent trend.
Wall Street analysts forecast DOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOX is 99 USD with a low forecast of 87 USD and a high forecast of 111 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast DOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOX is 99 USD with a low forecast of 87 USD and a high forecast of 111 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 81.070
Low
87
Averages
99
High
111
Current: 81.070
Low
87
Averages
99
High
111
Wolfe Research
Outperform -> Peer Perform
downgrade
$NULL
AI Analysis
2025-11-13
Reason
Wolfe Research
Price Target
$NULL
AI Analysis
2025-11-13
downgrade
Outperform -> Peer Perform
Reason
Wolfe Research downgraded Amdocs to Peer Perform from Outperform without a price target. The firm says its near-term enthusiasm for the shares has "waned" since the company has sales growth acceleration or margin expansion embedded in its fiscal 2026 guidance. In addition, the T-Mobile commentary "heightens concerns, the analyst tells investors in a research note. Wolfe cites a lack of catalysts for the downgrade.
BofA
Buy
downgrade
$100 -> $97
2025-11-12
Reason
BofA
Price Target
$100 -> $97
2025-11-12
downgrade
Buy
Reason
BofA lowered the firm's price target on Amdocs to $97 from $100 and keeps a Buy rating on the shares. Growth remains constrained and the FY26 guidance for revenue growth and EPS, at 3.7% and $7.44, were below the Street's forecasts of 4.1% and $7.66, respectively, notes the analyst, who expects the year to start slow and ramp in the second half.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOX
